Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy
Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy
复制标题
基于单域抗体的 TCR 类 CAR-T：一种潜在的癌症疗法
DOI：
10.1155/2020/2454907
复制
发表时间：
2020-09
影响因子：
4.1
通讯作者：
Xiaoling Lu
中科院分区：
文献类型：
--
作者：
Lichen Zhu;Xiaomei Yang;Dani Zhong;Shenxia Xie;Wei Shi;Yangzi Li;Xiaoqiong Hou;HuaYao;Huihui Zhou;Minlong Zhao;Ziqiang Ding;Xinyue Zhao;Fengzhen Mo;Shihua Yin;Aiqun Liu;Xiaoling Lu
通过工程化嵌合抗原受体（CAR）（也称为TCR样抗体CAR-T）将T细胞的抗原结合特异性重新靶向降解并呈递在肿瘤表面上的细胞内抗原仍然有限。除了用于血液恶性肿瘤的商业化CD 19 CAR-T和其他主要针对细胞外抗原的CAR-T疗法取得了巨大成功外，TCR样CAR-T疗法的罕见和稀缺可能是由于其目前的状态和局限性。这篇综述提供了改善TCR样CAR-T重编程的可能优化方案，并讨论了作为传统scFv的替代品并由CAR-T细胞分泌的单域抗体，这可能对开发针对细胞内抗原的CAR-T免疫疗法具有重要价值。
Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited. With the exception of the commercialized CD19 CAR-T for hematological malignancies and other CAR-T therapies aiming mostly at extracellular antigens achieving great success, the rareness and scarcity of TCR-like CAR-T therapies might be due to their current status and limitations. This review provides the probable optimized initiatives for improving TCR-like CAR-T reprogramming and discusses single-domain antibodies administered as an alternative to conventional scFvs and secreted by CAR-T cells, which might be of great value to the development of CAR-T immunotherapies for intracellular antigens.
登录
查看更多内容
影响因子：
4
作者：
Hassani, Mahmoud;Taheri, Fatemeh Hajari;Abolhassani, Mohsen
通讯作者：
Abolhassani, Mohsen
影响因子：
--
作者：
Xu Y;Salazar GT;Zhang N;An Z
通讯作者：
An Z
影响因子：
4.6
作者：
Chang AY;Gejman RS;Brea EJ;Oh CY;Mathias MD;Pankov D;Casey E;Dao T;Scheinberg DA
通讯作者：
Scheinberg DA
影响因子：
4.5
作者：
Ma Q;Garber HR;Lu S;He H;Tallis E;Ding X;Sergeeva A;Wood MS;Dotti G;Salvado B;Ruisaard K;Clise-Dwyer K;John LS;Rezvani K;Alatrash G;Shpall EJ;Molldrem JJ
通讯作者：
Molldrem JJ
影响因子：
11.4
作者：
Zhao Q;Ahmed M;Tassev DV;Hasan A;Kuo TY;Guo HF;O'Reilly RJ;Cheung NK
通讯作者：
Cheung NK